Pacific Biosciences Of California (PACB) Gains from Sales and Divestitures (2019 - 2022)

Pacific Biosciences Of California has reported Gains from Sales and Divestitures for 4 years, with the latest figure at $2.6 million in Q4 2022.

• For the quarter ending Q4 2022, Gains from Sales and Divestitures rose 43.6% year-over-year to $2.6 million; the trailing twelve-month figure through Dec 2022 stood at $2.6 million (up 43.6% YoY), and the FY2022 full-year result was $2.6 million, up 43.6% from the prior year.
• Gains from Sales and Divestitures for Q4 2022 stood at $2.6 million, up from $2.4 million in the prior quarter.
• The five-year high for Gains from Sales and Divestitures was $2.6 million in Q4 2022, with the low at $2026.0 in Q2 2022.
• Average Gains from Sales and Divestitures over 4 years is $1.1 million, with a median of $876000.0 recorded in 2020.
• Year-over-year, Gains from Sales and Divestitures soared 390.2% in 2020 and tumbled 99.86% in 2022.
• Tracing PACB's Gains from Sales and Divestitures over 4 years: stood at $204000.0 in 2019, then surged by 390.2% to $1.0 million in 2020, then surged by 79.8% to $1.8 million in 2021, then jumped by 43.6% to $2.6 million in 2022.
• The last three Gains from Sales and Divestitures figures came in at $2.6 million (Q4 2022), $2.4 million (Q3 2022), and $2026.0 (Q2 2022), per Business Quant data.

Peer Comparison